Frazier Life Sciences Appoints Christian Schade as Senior Advisor
Aprea Therapeutics, Inc. (APRE)
Company Research
Source: Business Wire
PALO ALTO, Calif.--(BUSINESS WIRE)--Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Christian Schade as Senior Advisor. Chris will join FLS’ Boston office and work closely with the firm’s portfolio companies on corporate strategy and business development.“Chris brings deep operational and financial experience with both private and public biopharma companies,” said Joe Cabral, Partner at Frazier Life Sciences. “His leadership experience and ability to guide companies through critical inflection points make him a strong addition to our advisory team. We’re pleased to welcome him as we continue building out our Boston team.”Mr. Schade joins Frazier Life Sciences with more than 30 years of experience in the pharmaceutical and biotechnology industries. Most recently, he served as President and Chief Executive Officer of Halda Therapeutics, a company developing a novel class of cancer therapies, where he
Show less
Read more
Impact Snapshot
Event Time:
APRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
APRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
APRE alerts
High impacting Aprea Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
APRE
News
- Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementGlobeNewswire
- Aprea Therapeutics (APRE) had its "outperform" rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.MarketBeat
- Aprea Therapeutics (APRE) had its price target lowered by HC Wainwright from $4.00 to $1.20. They now have a "buy" rating on the stock.MarketBeat
- Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Aprea Therapeutics Announces Oversubscribed $30 Million Private PlacementGlobeNewswire
APRE
Sec Filings
- 4/7/26 - Form SCHEDULE
- 4/1/26 - Form SCHEDULE
- 4/1/26 - Form 4
- APRE's page on the SEC website